ADTX Stock Risk & Deep Value Analysis
Aditxt Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ADTX Stock
We analyzed Aditxt Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ADTX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ADTX Risk Analysis & Red Flags
What Could Go Wrong
The company's severe cash burn and persistent net losses ($42.8M in 2025) mean it will run out of cash quickly. This will likely necessitate further massive dilution via the expanded ATM offering, which would severely depress the share price and risk delisting from Nasdaq if compliance cannot be maintained.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Going concern doubt flagged in 2025 10-K filing.
- ⚠
Nasdaq noncompliance risk due to low market capitalization and bid price (addressed by RS, but equity still a risk).
- ⚠
-$42.8M net loss on effectively $0 revenue in FY2025.
- ⚠
History of 1-for-8 reverse stock splits and continuous massive share dilution via ATM offerings.
- ⚠
Insufficient cash on hand for 12 months of operations.
Upcoming Risk Events
- 📅
Failure to regain Nasdaq compliance leading to delisting
- 📅
Further significant share dilution via expanded ATM offering
- 📅
Continued negative operating cash flow and worsening net losses
- 📅
Failure of Ignite Proteomics acquisition to generate expected revenue
When to Reconsider
- 🚪
Failure to achieve sustained Nasdaq compliance within 6 months.
- 🚪
Net loss continues to worsen or cash burn accelerates in subsequent quarters.
- 🚪
Announcement of further reverse stock splits or excessive dilution events (e.g., >20% new shares issued in a quarter).
- 🚪
Ignite Proteomics acquisition fails to generate meaningful revenue after 12 months of ownership.
Unlock ADTX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Aditxt Inc (ADTX) Do?
Market Cap
$713,000
Sector
Healthcare
Industry
Biotechnology
Employees
26
Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
Visit Aditxt Inc WebsiteInvestment Thesis
ADTX represents a highly speculative, high-risk bet on the successful integration and rapid commercialization of Ignite Proteomics' precision oncology platform. If Ignite can quickly generate significant revenue via Medicare reimbursement, mitigate Aditxt's massive cash burn, and the company can resolve its Nasdaq compliance issues without further excessive dilution, there is a theoretical, albeit low-probability, path to a multi-bagger return from current distressed levels. This is a pure turnaround play based on a new, unproven acquisition.
Is ADTX Stock Undervalued?
Unlock the full AI analysis for ADTX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ADTX Price Targets & Strategy
12-Month Target
$2.50
Bull Case
$5.00
Bear Case
$0.10
Valuation Basis
Implied valuation based on recent preferred stock conversion price ($2.731) and Nasdaq equity compliance targets, offset by severe financial distress.
Entry Strategy
Highly speculative, consider dollar-cost averaging on dips below $0.90, recognizing extreme volatility and risk.
Exit Strategy
Take profits on any significant price spikes above $2.00; set a tight stop-loss below $0.50 due to high delisting risk and cash burn.
Portfolio Allocation
0.1% for aggressive risk tolerance only, as part of a highly diversified, speculative portfolio.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does ADTX Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Nascent (The Ignite acquisition introduces potential, but the company's overall financial health and history erode any existing or potential moats.)
Moat Sources
3 Identified
Highly questionable. Aditxt's severe financial instability, ongoing losses, and capital constraints significantly hinder the development and durability of any competitive advantages. Ignite's nascent moat is highly vulnerable to competition and lack of funding.
Moat Erosion Risks
- •Intense competition from well-capitalized established players in precision oncology.
- •Lack of funding for crucial R&D, commercialization, and scaling of Ignite's platform.
- •Failure to demonstrate clear clinical utility and cost-effectiveness of Ignite's tests to drive adoption.
ADTX Competitive Moat Analysis
Sign up to see competitive advantages
ADTX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (Likely negative retail sentiment given consistent value destruction and financial instability)
Institutional Sentiment
Negative (No analyst coverage, no reported institutional ownership %, high short interest indicated).
Insider Activity (Form 4)
No Form 4 filings reported in the last 90 days (Jan 3-Apr 2, 2026).
Options Flow
Normal options activity (No specific data available indicating unusual activity).
Earnings Intelligence
Next Earnings
No data available; next report likely Q1 2026 (~May 2026)
Surprise Probability
Low (Given persistent losses and lack of analyst estimates, any positive surprise would be unexpected and significant).
Historical Earnings Pattern
Historically, stock price has reacted negatively to consistent losses and dilution, with any potential rallies likely short-lived unless fundamental financial improvements are shown.
Key Metrics to Watch
Competitive Position
Top Competitor
Undetermined (Given the shift to precision oncology, potential competitors include Guardant Health, Natera, Caris Life Sciences, but no direct comparison data available).
Market Share Trend
Negligible/None (ADTX previously had minimal revenue; Ignite's market share is nascent and unquantified).
Valuation vs Peers
N/A (Trading at extreme distress valuation due to negligible revenue and severe losses; traditional valuation metrics are not applicable).
Competitive Advantages
- •CLIA-certified lab (from Ignite acquisition)
- •Medicare reimbursement for precision oncology tests (from Ignite acquisition)
- •Proprietary proteomics platform (from Ignite acquisition)
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ADTX Stock Higher?
Near-Term (0-6 months)
- •First reported revenue from Ignite Proteomics (expected late 2026/early 2027)
- •Successful and sustained regaining of Nasdaq bid price and equity compliance
Medium-Term (6-18 months)
- •Expansion of Ignite Proteomics test adoption and Medicare reimbursement volumes
- •Announcement of strategic partnerships for Ignite's platform
Long-Term (18+ months)
- •Significant market penetration in precision oncology by Ignite Proteomics
- •Achievement of sustainable profitability and positive free cash flow
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ADTX?
- ✓
Consistent positive growth in Ignite Proteomics test volumes and associated revenue.
- ✓
Significant reduction in overall operating expenses and cash burn rate.
- ✓
Sustained Nasdaq compliance without further reverse splits or excessive dilution.
- ✓
Announcement of key clinical data or major commercial partnerships for Ignite.
Bull Case Analysis
See what could go right with Premium
Competing with ADTX
See how Aditxt Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Aditxt Inc ADTX | $713,000 | 0.4 | — | $12,051 | 0.0% | -79.2% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $154.6B | 0.2 | 19.9 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Aditxt Inc (ADTX)?
As of April 2, 2026, Aditxt Inc has a DVR Score of 0.4 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Aditxt Inc?
Aditxt Inc's market capitalization is approximately $713,000. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Aditxt Inc use?
ADTX is the ticker symbol for Aditxt Inc. The company trades on the NCM.
What is the risk level for ADTX stock?
Our analysis rates Aditxt Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Aditxt Inc's revenue growing?
Aditxt Inc has reported revenue growth of -79.2%. Revenue has been declining, which warrants closer examination.
Is ADTX stock profitable?
Aditxt Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the ADTX DVR analysis updated?
Our AI-powered analysis of Aditxt Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 2, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ADTX (Aditxt Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.